Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel P Hart

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 22, 2023
Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow-up from the UK Haemophilia Centre Doctors' Organisation (UKHCDO)Caroline Wall, Hua Xiang, Ben Palmer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 2, 2021
Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disordersRadoslaw Kaczmarek, Magdy El Ekiaby, Daniel P Hart, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 9, 2019
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studiesPeter Volkers, Kay-Martin Hanschmann, Thierry Calvez, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 17, 2021
Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus updateDaniel P Hart, Jayanthi Alamelu, Neha Bhatnagar, et al.
Thrombosis and Haemostasis|April 17, 2015
Inhibitors in nonsevere haemophilia A: outcome and eradication strategiesAlice S van Velzen, Corien L Eckhardt, Daniel P Hart, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerationsAlfonso Iorio, Andrea N Edginton, Victor Blanchette, et al.
Haematologica|April 18, 2020
Identification of a homozygous recessive variant in <i>PTGS1</i> resulting in a congenital aspirin-like defect in platelet functionMelissa V Chan, Melissa A Hayman, Suthesh Sivapalaratnam, et al.
Blood|January 9, 2017
Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopeniaSuthesh Sivapalaratnam, Sarah K Westbury, Jonathan C Stephens, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 6, 2021
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitorsMiguel Escobar, James Luck, Yevhenii Averianov, et al.
The New England Journal of Medicine|February 22, 2023
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia BSteven W Pipe, Frank W G Leebeek, Michael Recht, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 22, 2023
Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow-up from the UK Haemophilia Centre Doctors' Organisation (UKHCDO)Caroline Wall, Hua Xiang, Ben Palmer, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 2, 2021
Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disordersRadoslaw Kaczmarek, Magdy El Ekiaby, Daniel P Hart, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 9, 2019
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studiesPeter Volkers, Kay-Martin Hanschmann, Thierry Calvez, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 17, 2021
Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus updateDaniel P Hart, Jayanthi Alamelu, Neha Bhatnagar, et al.
Thrombosis and Haemostasis|April 17, 2015
Inhibitors in nonsevere haemophilia A: outcome and eradication strategiesAlice S van Velzen, Corien L Eckhardt, Daniel P Hart, et al.
Research and Practice in Thrombosis and Haemostasis|July 27, 2018
Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerationsAlfonso Iorio, Andrea N Edginton, Victor Blanchette, et al.
Haematologica|April 18, 2020
Identification of a homozygous recessive variant in <i>PTGS1</i> resulting in a congenital aspirin-like defect in platelet functionMelissa V Chan, Melissa A Hayman, Suthesh Sivapalaratnam, et al.
Blood|January 9, 2017
Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopeniaSuthesh Sivapalaratnam, Sarah K Westbury, Jonathan C Stephens, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 6, 2021
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitorsMiguel Escobar, James Luck, Yevhenii Averianov, et al.
The New England Journal of Medicine|February 22, 2023
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia BSteven W Pipe, Frank W G Leebeek, Michael Recht, et al.
Pageof 5